TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34850166

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) and VDX (10 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) and VDX (10 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) and VDX (20 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nivolumab (all doses) and VDX (all doses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nivolumab and VDX
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: VDX
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IL-12 gene therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Post-treatment biopsies
Number of subjects: 21
Study: 34850167

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 33
Study: 34850325

Group type: EXPERIMENTAL
Intervention: HBV-specific TCR redirected T (HBV-TCR-T) cells
Number of subjects: 8
Study: 34850380

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic treatment
Number of subjects: 980

Group type: COMPARATOR
Intervention: Control
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 980
Study: 34850616

Group type: EXPERIMENTAL
Intervention: IDS-hGH on iSYS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: LIAISON-hGH on Liaison XL
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Elecsys ROCHE-hGH on COBAS 8000
Number of subjects: 39

Group type: COMPARATOR
Intervention: Elecsys Roche-hGH method
Number of subjects: 39
Study: 34850742

Group type: EXPERIMENTAL
Intervention: HIV-1 envelope (Env) plasmid DNA prime and recombinant modified vaccinia virus Ankara (MVA) boost
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recombinant MVA expressing a heterologous Env
Number of subjects: 20
Study: 34850966

Group type: EXPERIMENTAL
Intervention: SNOT-22 rhinologic symptoms domain
Number of subjects: 0
Study: 34851726

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Number of subjects: 167
Study: 34852172

Group type: EXPERIMENTAL
Intervention: CCX168
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C5a/C5aR1 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C5a/C5aR1
Number of subjects: 0
Study: 34852175

Group type: EXPERIMENTAL
Intervention: AD disease
Number of subjects: 231

Group type: COMPARATOR
Intervention: AR/XLR and TINF2 disease
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 231
Study: 34852305

Group type: EXPERIMENTAL
Intervention: High-intensity bridging chemotherapy (≥2 cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity bridging chemotherapy (1 cycle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bridging chemotherapy (both intensities)
Number of subjects: 0
Study: 34852758

Group type: EXPERIMENTAL
Intervention: Hypoxia training group (HT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Normoxia training group (NT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 54
Study: 34852837

Group type: EXPERIMENTAL
Intervention: Baseline tau PET imaging
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cognitively normal controls
Number of subjects: 67
Study: 34853024

Group type: EXPERIMENTAL
Intervention: Financial incentives group (n=231)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (n=229)
Number of subjects: 460
Study: 34853082

Group type: EXPERIMENTAL
Intervention: Optimised preventive treatment strategy (treating arteries instead of risk factors)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Plaque thickness
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Older age, male sex, greater plaque thickness, coronary heart disease, vascular surgery/stenting history, smoking
Number of subjects: 1391
Study: 34853102

Group type: EXPERIMENTAL
Intervention: AZD1656 (glucokinase activator)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Matched placebo tablets
Number of subjects: 150
Study: 34853114

Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34853376

Group type: EXPERIMENTAL
Intervention: Single intravenous access iohexol GFR measurement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Single intravenous access iohexol GFR measurement after blood discarding and saline flushing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Blood sampling from a second intravenous access
Number of subjects: 31
Study: 34853430

Group type: EXPERIMENTAL
Intervention: SNPs associated with BPD risk at allele level (8 SNPs identified)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: SNPs rs4883955 on KLF12 and rs9953270 on CHST9
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: SNPs on MBL2, NFKBIA, CEP170, MAGI2, and VEGFA genes
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: SNPs on CHST9 and KLF12 genes
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Functional relationship of genes harboring SNPs with WNT5A
Number of subjects: 192
Study: 34853511

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory anti-diabetic medication (including metformin)
Number of subjects: 2222

Group type: EXPERIMENTAL
Intervention: Metformin-containing therapy
Number of subjects: 2222

Group type: COMPARATOR
Intervention: Oral anti-diabetic medication (overall)
Number of subjects: 2222
Study: 34853799

Group type: EXPERIMENTAL
Intervention: Nusinersen and/or onasemnogene abeparvovec
Number of subjects: 103

Group type: COMPARATOR
Intervention: Healthy control infants
Number of subjects: 103

Group type: COMPARATOR
Intervention: Untreated SMA infants
Number of subjects: 103
Study: 34853986

Group type: EXPERIMENTAL
Intervention: Cryoballoon (POLARx™; Boston Scientific)
Number of subjects: 69
Study: 34854079

Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone (HD-DXM)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: HD-DXM plus recombinant human thrombopoietin
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: standard-dose rituximab
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: low-dose rituximab
Number of subjects: 725
Study: 34854315

Group type: EXPERIMENTAL
Intervention: QRSA+
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: TWA+
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: QRSA+ and TWA+ together
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: QRSA magnitude
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Appropriate ICD therapy
Number of subjects: 130
Study: 34854418

Group type: EXPERIMENTAL
Intervention: Fresh gas flow rate at 3 L/min with HME attached
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fresh gas flow rate at 6 L/min with HME attached
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fresh gas flow rate at 3 L/min without HME
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fresh gas flow rate at 6 L/min without HME
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HME (+) regardless of anesthetic agent
Number of subjects: 240

Group type: COMPARATOR
Intervention: HME (-) regardless of anesthetic agent
Number of subjects: 240
Study: 34854473

Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 908

Group type: COMPARATOR
Intervention: SCS + other intervention
Number of subjects: 908

Group type: COMPARATOR
Intervention: SCS
Number of subjects: 908
Study: 34854740

Group type: EXPERIMENTAL
Intervention: Engineered mesoporous silica (SiPore15)
Number of subjects: 0
Study: 34854746

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-Guided Biopsy (MRGBx)
Number of subjects: 519
Study: 34854790

Group type: EXPERIMENTAL
Intervention: COVID-19 pneumonia
Number of subjects: 103

Group type: COMPARATOR
Intervention: non-COVID-19 pneumonia
Number of subjects: 103
Study: 34854816

Group type: EXPERIMENTAL
Intervention: how2trak postoperative monitoring
Number of subjects: 29

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 29
Study: 34854818

Group type: EXPERIMENTAL
Intervention: Vaccination with the Pfizer vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental analysis of innate immune response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiological analysis of vaccination history
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical analysis of immunological profile
Number of subjects: 0
Study: 34854918

Group type: EXPERIMENTAL
Intervention: Standardized clinical care pathway
Number of subjects: 203
Study: 34855038

Group type: EXPERIMENTAL
Intervention: Near Vision Presbyopia Task-based Questionnaire (NVPTQ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NVPTQ domain scores
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NVPTQ Performance and Satisfaction domain scores
Number of subjects: 20
Study: 34855461

Group type: EXPERIMENTAL
Intervention: CD123 expression quartile 4 (Q4)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: CD123 expression
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1040
Study: 34855617

Group type: EXPERIMENTAL
Intervention: Text-messaging protocol incorporating narratives from Veterans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrative messages, nonnarrative educational messages, and 2-way interactive messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally sensitive text-messaging protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial underway
Number of subjects: 0
Study: 34855619

Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcome mobile app
Number of subjects: 0
Study: 34855624

Group type: EXPERIMENTAL
Intervention: High-titer COVID-19 convalescent plasma (>1:320 anti-spike IgG) transfusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-titer COVID-19 convalescent plasma transfusion
Number of subjects: 14
Study: 34855649

Group type: EXPERIMENTAL
Intervention: Higher baseline levels of social withdrawal
Number of subjects: 4461

Group type: COMPARATOR
Intervention: Short-term psychopharmacological treatment (12 weeks)
Number of subjects: 4461
Study: 34855787

Group type: EXPERIMENTAL
Intervention: Homophobic victimization
Number of subjects: 747
Study: 34856587

Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 94

Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 94

Group type: COMPARATOR
Intervention: Hospital costs for delayed surgery
Number of subjects: 94
Study: 34857190

Group type: EXPERIMENTAL
Intervention: Nutrition intervention via an app
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study: 34857214

Group type: EXPERIMENTAL
Intervention: Oral Iron Absorption Test (OIAT) combined with Oral Glucose Tolerance Test (OGTT) measuring ΔSeFe after an oral iron dose of 6 mg.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Fractional Iron Absorption (FIA) using stable iron isotopes from a labeled iron dose.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Oral Iron Absorption Test (OIAT)
Number of subjects: 116
Study: 34857236

Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 34857357

Group type: EXPERIMENTAL
Intervention: hs-cTnT measured before and days 0-3 after surgery
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: hs-cTnT thresholds evaluated
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Revised Cardiac Risk Index (RCRI)
Number of subjects: 1291
Study: 34857432

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 396 days post-MI
Number of subjects: 7708

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 5 years post-MI
Number of subjects: 7708

Group type: EXPERIMENTAL
Intervention: DAPT use in relation to age and treatment type
Number of subjects: 7708

Group type: EXPERIMENTAL
Intervention: Geographic variations in DAPT use
Number of subjects: 7708
Study: 34857438

Group type: EXPERIMENTAL
Intervention: Chronic motor dysfunction (n=40, 59%)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Elevated transaminases (n=7, 10%)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Acute/intermittent symptoms (n=21, 31%)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Febrile illness-associated acute weakness
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall population (n=68)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Patients with symptom onset in the 1970s
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Patients with symptom onset after 2000
Number of subjects: 68
Study: 34857473

Group type: EXPERIMENTAL
Intervention: Registry of secondary revascularization (REVASEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management including medical treatment and secondary revascularization (SR)
Number of subjects: 0
Study: 34857533

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 29
Study: 34857554

Group type: EXPERIMENTAL
Intervention: Feeding promotion tailored to meet the nutritional needs of LBW infants
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Observational cohort study
Number of subjects: 12
Study: 34857584

Group type: EXPERIMENTAL
Intervention: CCEDRRN COVID-19 Infection Score derived from 21,743 patients
Number of subjects: 27665

Group type: EXPERIMENTAL
Intervention: External validation of CCEDRRN COVID-19 Infection Score in 5,295 patients
Number of subjects: 27665
Study: 34857585

Group type: EXPERIMENTAL
Intervention: Octreotide infusion during liver transplantation surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infusion during liver transplantation surgery
Number of subjects: 30
Study: 34857656

Group type: EXPERIMENTAL
Intervention: First-line immunochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients not achieving CMR
Number of subjects: 0
Study: 34857658

Group type: EXPERIMENTAL
Intervention: urokinase-type plasminogen activator receptor (uPAR) PET/CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34857666

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 934

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 934
Study: 34857684

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 0
Study: 34857814

Group type: EXPERIMENTAL
Intervention: Fecal microbiota in girls during puberty
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Fecal microbiota in boys during puberty
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Relative abundance of estrogen-metabolizing Clostridia in both sexes
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Exposure to cephalosporins prior to age 10 in girls
Number of subjects: 148
Study: 34857877

Group type: EXPERIMENTAL
Intervention: ELBW cases
Number of subjects: 180
Study: 34858178

Group type: EXPERIMENTAL
Intervention: Immunotherapy combined with antiangiogenic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34858205

Group type: EXPERIMENTAL
Intervention: Home-based high-intensity interval training (Home-HIIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 0
Study: 34858350

Group type: EXPERIMENTAL
Intervention: Two-step screening strategy with GCT
Number of subjects: 1804

Group type: COMPARATOR
Intervention: One-step screening strategy with OGTT
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: One-step screening with OGTT
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Two-step screening with GCT
Number of subjects: 1804
Study: 34858423

Group type: EXPERIMENTAL
Intervention: Dendritic Cell-Based HIV Vaccine in combination with Pegylated Interferon α-2a
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 34858433

Group type: EXPERIMENTAL
Intervention: Medium Cut-Off (MCO) membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-Flux (HF) membranes
Number of subjects: 0
Study: 34858523

Group type: EXPERIMENTAL
Intervention: Oral glutamine (gln) powder 15 g bid for the full duration of treatment
Number of subjects: 72
Study: 34858805

Group type: EXPERIMENTAL
Intervention: Elective radical resection of advanced digestive system cancer
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model
Number of subjects: 839
Study: 34858829

Group type: EXPERIMENTAL
Intervention: neoadjuvant concurrent chemoradiotherapy (nCRT)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 149
Study: 34858837

Group type: EXPERIMENTAL
Intervention: High-frequency irreversible electroporation (H-FIRE) ablation
Number of subjects: 110
Study: 34859035

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 34859043

Group type: EXPERIMENTAL
Intervention: Fast-Track protocol in minimally invasive gynecology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 0
Study: 34859113

Group type: EXPERIMENTAL
Intervention: Perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Single dose of cefazolin
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Intensification of prophylaxis
Number of subjects: 177
Study: 34859204

Group type: EXPERIMENTAL
Intervention: Soft shoe version
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hard shoe version
Number of subjects: 800
Study: 34859288

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the laryngeal motor cortex (LMC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no rTMS)
Number of subjects: 13
Study: 34859304

Group type: EXPERIMENTAL
Intervention: Quantra® Hemostasis Analyzer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional coagulation tests
Number of subjects: 0
Study: 34859498

Group type: EXPERIMENTAL
Intervention: Unilateral subthalamotomy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 86
Study: 34859612

Group type: COMPARATOR
Intervention: GLPG1972 (≤2100 mg [fasted] and 300 mg [fed] single doses; ≤1050 mg once daily [fed] for 14 days)
Number of subjects: 159

Group type: COMPARATOR
Intervention: GLPG1972 (≤300 mg once daily [fed] for 4 weeks)
Number of subjects: 159

Group type: COMPARATOR
Intervention: GLPG1972 (≤1500 mg single dose for Japanese; 300 mg single dose for White; ≤1050 mg once daily for Japanese; 300 mg once daily for White for 14 days)
Number of subjects: 159
Study: 34860120

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Number of subjects: 0
Study: 34860130

Group type: EXPERIMENTAL
Intervention: Behavioral Gamification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34860418

Group type: EXPERIMENTAL
Intervention: High-dose LNF (≥75 mg po bid + RTV) for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All-oral low-dose LNF (25 or 50 mg po bid + RTV) for 24 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination low-dose LNF (25 or 50 mg po bid + RTV + PEG-IFNα) for 24 weeks
Number of subjects: 55
Study: 34860739

Group type: COMPARATOR
Intervention: Iopromide administration in children
Number of subjects: 132850

Group type: COMPARATOR
Intervention: Iopromide administration in elderly
Number of subjects: 132850

Group type: EXPERIMENTAL
Intervention: Iopromide administration in adults
Number of subjects: 132850

Group type: COMPARATOR
Intervention: Overall iopromide administrations in children
Number of subjects: 132850

Group type: COMPARATOR
Intervention: Overall iopromide administrations in elderly
Number of subjects: 132850

Group type: EXPERIMENTAL
Intervention: Overall iopromide administrations in adults
Number of subjects: 132850
Study: 34860815

Group type: EXPERIMENTAL
Intervention: Pancreatic Quantitative Sensory Testing (P-QST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P-QST
Number of subjects: 0
Study: 34861073

Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Endogenous circadian rhythms
Number of subjects: 6
Study: 34861146

Group type: EXPERIMENTAL
Intervention: Pancreatic endoderm cells (PECs) implanted subcutaneously with immunosuppressive regimen
Number of subjects: 15
Study: 34861151

Group type: EXPERIMENTAL
Intervention: Add on heart failure therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background therapy
Number of subjects: 0
Study: 34861154

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg per day
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 34861408

Group type: EXPERIMENTAL
Intervention: HomeStyles intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study: 34861829

Group type: EXPERIMENTAL
Intervention: Diet consisting of cereals and meat products
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fibre intake
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Red and processed meat intake
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gluten-containing cereals intake
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Butyrate levels in faeces (absolute concentration)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Butyrate levels in faeces (relative abundance)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Levels of gluten immunogenic peptide and starch in faeces
Number of subjects: 14
Study: 34862245

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line (given weekly for 4 weeks, then every 8 weeks until depletion or disease progression)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line
Number of subjects: 36
Study: 34862279

Group type: COMPARATOR
Intervention: Community-based intervention to increase EOCRC awareness delivered via outdoor mass media and social media.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Quantitative data analysis from Utah Cancer Registry and National Cancer Institute Surveillance, Epidemiology and End Results registry.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: One-on-one interviews with EOCRC survivors.
Number of subjects: 34
Study: 34862278

Group type: EXPERIMENTAL
Intervention: Nasal povidone-iodine (PVI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 16